| Voyager Demonstrates ALPL Receptor-Mediated Blood-Brain Barrier Transport of Novel AAV Capsids in Molecular Therapy Publication |
LEXINGTON, Mass., May 15, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced the first peer-reviewed publication of data demonstrating the ability of alkaline phosphatase (ALPL) to transport a novel AAV capsid across the blood-brain barrier (BBB). The article, titled “Highly conserved brain vascular receptor ALPL mediates transport of engineered AAV vectors across the blood-brain barrier,” was published in Molecular Therapy and can be accessed here. |
globenewswire.com |
2025-05-15 11:00:00 |
Czytaj oryginał (ang.) |
| Voyager Therapeutics (VYGR) Reports Q1 Loss, Lags Revenue Estimates |
Voyager Therapeutics (VYGR) came out with a quarterly loss of $0.53 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to loss of $0.20 per share a year ago. |
zacks.com |
2025-05-06 22:10:45 |
Czytaj oryginał (ang.) |
| Voyager Reports First Quarter 2025 Financial and Operating Results |
– Tau silencing gene therapy VY1706 to be featured in oral presentation at ASGCT 2025; has shown up to 73% knockdown of tau mRNA in the CNS in NHPs following a single IV dose of 1.3e13 vg/kg – |
globenewswire.com |
2025-05-06 20:01:00 |
Czytaj oryginał (ang.) |
| Voyager Next-Generation CNS Capsids Featured at ASGCT 28th Annual Meeting |
- Oral presentation on tau silencing gene therapy VY1706, which has previously shown up to 73% knockdown of tau mRNA in NHPs in the CNS following a single IV dose of 1.3e13 vg/kg - |
globenewswire.com |
2025-04-28 20:30:00 |
Czytaj oryginał (ang.) |
| Voyager Presents Robust Preclinical Data from Tau Targeting Gene Therapy and Antibody Programs at AD/PD™ 2025 |
- Single IV administration of tau silencing gene therapy VY1706 significantly reduced tau mRNA and protein levels, with broad brain distribution and liver de-targeting, in NHP study - - Preclinical murine data strengthen case for specifically targeting pathologic forms of tau with the clinical-stage anti-tau antibody VY7523 - - Voyager to host live webcast on April 7 recapping key AD/PD™ 2025 data - LEXINGTON, Mass., March 31, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today reported new data from its two preclinical programs targeting tau for the treatment of Alzheimer's disease (AD). |
globenewswire.com |
2025-03-31 11:00:00 |
Czytaj oryginał (ang.) |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Voyager Therapeutics, Inc. - VYGR |
NEW YORK, NY / ACCESS Newswire / March 19, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Voyager Therapeutics, Inc ("Voyager" or the "Company") (NASDAQ:VYGR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accessnewswire.com |
2025-03-19 12:00:00 |
Czytaj oryginał (ang.) |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Voyager Therapeutics, Inc. - VYGR |
NEW YORK , March 17, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Voyager Therapeutics, Inc ("Voyager" or the "Company") (NASDAQ: VYGR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
prnewswire.com |
2025-03-17 17:03:00 |
Czytaj oryginał (ang.) |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Voyager Therapeutics, Inc. - VYGR |
NEW YORK, NY / ACCESS Newswire / March 15, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Voyager Therapeutics, Inc ("Voyager" or the "Company") (NASDAQ:VYGR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accessnewswire.com |
2025-03-15 12:00:00 |
Czytaj oryginał (ang.) |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Voyager Therapeutics, Inc. - VYGR |
NEW YORK CITY, NY / ACCESS Newswire / March 13, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Voyager Therapeutics, Inc ("Voyager" or the "Company") (NASDAQ:VYGR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accessnewswire.com |
2025-03-13 16:30:00 |
Czytaj oryginał (ang.) |
| Voyager Therapeutics, Inc. (VYGR) Q4 2024 Earnings Call Transcript |
Voyager Therapeutics, Inc. (NASDAQ:VYGR ) Q4 2024 Earnings Conference Call March 11, 2025 4:30 PM ET Company Participants Trista Morrison - Chief Corporate Affairs Officer and Chief of Staff to the CEO Alfred Sandrock - President and Chief Executive Officer Toby Ferguson - Chief Medical Officer Todd Carter - Chief Scientific Officer Nathan Jorgensen - Chief Financial Officer Conference Call Participants Jack Allen - Robert W. Baird Phil Nadeau - TD Cowen Pete Stavropoulos - Cantor Fitzgerald Lili Nsongo - Leerink Partners Samantha Semenkow - Citi Mehdi Goudarzi - Truist Securities Ry Forseth - Guggenheim Securities Jay Olson - Oppenheimer & Co. Patrick Trucchio - HC Wainwright & Co. Yun Zhong - Wedbush Sciences Yanan Zhu - Wells Fargo Securities Sumant Kulkarni - Canaccord Genuity Operator Good afternoon, and welcome to Voyager Therapeutics Fourth Quarter and Year-End 2024 Financial Results Conference Call. |
seekingalpha.com |
2025-03-11 21:35:23 |
Czytaj oryginał (ang.) |
| Voyager Therapeutics (VYGR) Reports Q4 Loss, Misses Revenue Estimates |
Voyager Therapeutics (VYGR) came out with a quarterly loss of $0.59 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to earnings of $1.25 per share a year ago. |
zacks.com |
2025-03-11 20:10:19 |
Czytaj oryginał (ang.) |
| Voyager Reports Fourth Quarter and Full Year 2024 Financial and Operating Results |
- Tau silencing gene therapy VY1706 robustly reduced tau mRNA levels, with broad distribution, and was well-tolerated in NHP study; IND filing anticipated in 2026 - |
globenewswire.com |
2025-03-11 18:01:00 |
Czytaj oryginał (ang.) |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Voyager Therapeutics, Inc. - VYGR |
NEW YORK , March 11, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Voyager Therapeutics, Inc ("Voyager" or the "Company") (NASDAQ: VYGR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
prnewswire.com |
2025-03-11 14:19:00 |
Czytaj oryginał (ang.) |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Voyager Therapeutics, Inc. - VYGR |
NEW YORK, NY / ACCESS Newswire / March 7, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Voyager Therapeutics, Inc ("Voyager" or the "Company") (NASDAQ:VYGR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accessnewswire.com |
2025-03-07 12:00:00 |
Czytaj oryginał (ang.) |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Voyager Therapeutics, Inc. - VYGR |
NEW YORK, NY / ACCESS Newswire / March 5, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Voyager Therapeutics, Inc ("Voyager" or the "Company") (NASDAQ:VYGR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accessnewswire.com |
2025-03-05 16:30:00 |
Czytaj oryginał (ang.) |
| Voyager Therapeutics Announces Fourth Quarter 2024 Conference Call and Webcast |
LEXINGTON, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced it will report fourth quarter 2024 financial and operating results after market close on Tuesday, March 11, 2025. |
globenewswire.com |
2025-03-04 09:00:00 |
Czytaj oryginał (ang.) |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Voyager Therapeutics, Inc. - VYGR |
NEW YORK , March 3, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Voyager Therapeutics, Inc ("Voyager" or the "Company") (NASDAQ: VYGR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
prnewswire.com |
2025-03-03 16:40:00 |
Czytaj oryginał (ang.) |
| Voyager Reports Positive Topline Data for Single Ascending Dose (SAD) Trial of Anti-Tau Antibody VY7523 and Initiates Multiple Ascending Dose (MAD) Trial in Alzheimer's Disease |
- Topline SAD data from healthy volunteers demonstrate safety, tolerability, and dose-proportional pharmacokinetics, supporting potentially best-in-class profile - |
globenewswire.com |
2025-03-03 09:00:00 |
Czytaj oryginał (ang.) |
| The Schall Law Firm Invites Shareholders With Losses In Voyager Therapeutics, Inc. To Join A Securities Fraud Investigation |
LOS ANGELES, CA / ACCESS Newswire / March 2, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Voyager Therapeutics, Inc. ("Voyager" or "the Company") (NASDAQ:VYGR) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. |
accessnewswire.com |
2025-03-02 13:00:00 |
Czytaj oryginał (ang.) |
| An Investigation Has Been Launched Into Voyager Therapeutics, Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm |
LOS ANGELES, CA / ACCESS Newswire / March 1, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Voyager Therapeutics, Inc. ("Voyager" or "the Company") (NASDAQ:VYGR) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. |
accessnewswire.com |
2025-03-01 13:00:00 |
Czytaj oryginał (ang.) |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Voyager Therapeutics, Inc. - VYGR |
NEW YORK, NY / ACCESS Newswire / February 27, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Voyager Therapeutics, Inc ("Voyager" or the "Company") (NASDAQ:VYGR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accessnewswire.com |
2025-02-27 12:15:00 |
Czytaj oryginał (ang.) |
| An Investigation Has Been Launched Into Voyager Therapeutics, Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm |
LOS ANGELES, CA / ACCESS Newswire / February 27, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Voyager Therapeutics, Inc. ("Voyager" or "the Company") (NASDAQ:VYGR) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. |
accessnewswire.com |
2025-02-27 12:00:00 |
Czytaj oryginał (ang.) |
| Did Voyager Therapeutics, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate - VYGR |
NEW YORK, NY / ACCESS Newswire / February 26, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Voyager Therapeutics, Inc. ("Voyager Therapeutics, Inc.") (NASDAQ:VYGR) concerning possible violations of federal securities laws. Voyager issued a press release on February 11, 2025, "announc[ing] it has decided to assess alternate payloads related to its gene therapy program for superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS)", stating that "[e]merging preclinical data indicate the siRNA payload component of VY9323 does not meet our high standards due to what appears to be an off-target effect resulting in a narrowed therapeutic window. |
accessnewswire.com |
2025-02-26 12:30:00 |
Czytaj oryginał (ang.) |
| Voyager Therapeutics, Inc. Being Investigated on Behalf of Voyager Therapeutics, Inc. Investors. Contact Levi & Korsinsky For Details |
NEW YORK, NY / ACCESS Newswire / February 25, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Voyager Therapeutics, Inc. ("Voyager Therapeutics, Inc.") (NASDAQ:VYGR) concerning possible violations of federal securities laws. Voyager issued a press release on February 11, 2025, "announc[ing] it has decided to assess alternate payloads related to its gene therapy program for superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS)", stating that "[e]merging preclinical data indicate the siRNA payload component of VY9323 does not meet our high standards due to what appears to be an off-target effect resulting in a narrowed therapeutic window. |
accessnewswire.com |
2025-02-25 19:30:00 |
Czytaj oryginał (ang.) |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Voyager Therapeutics, Inc. - VYGR |
NEW YORK , Feb. 25, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Voyager Therapeutics, Inc ("Voyager" or the "Company") (NASDAQ: VYGR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
prnewswire.com |
2025-02-25 19:00:00 |
Czytaj oryginał (ang.) |
| Investors who Lost Money on Voyager Therapeutics, Inc. Should Contact Levi & Korsinsky About an Ongoing Investigation - VYGR |
NEW YORK, NY / ACCESS Newswire / February 25, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Voyager Therapeutics, Inc. ("Voyager Therapeutics, Inc.") (NASDAQ:VYGR) concerning possible violations of federal securities laws. Voyager issued a press release on February 11, 2025, "announc[ing] it has decided to assess alternate payloads related to its gene therapy program for superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS)", stating that "[e]merging preclinical data indicate the siRNA payload component of VY9323 does not meet our high standards due to what appears to be an off-target effect resulting in a narrowed therapeutic window. |
accessnewswire.com |
2025-02-25 12:30:00 |
Czytaj oryginał (ang.) |
| Voyager Therapeutics to Present at Multiple Upcoming Investor Conferences |
LEXINGTON, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the Company will participate in multiple upcoming investor conferences: TD Cowen 45th Annual Health Care Conference, in Boston, including a fireside chat at 1:50 p.m. |
globenewswire.com |
2025-02-25 09:00:00 |
Czytaj oryginał (ang.) |
| An Investigation Has Commenced on Behalf of Voyager Therapeutics, Inc. Shareholders. Contact Levi & Korsinsky to Discuss your VYGR Losses. |
NEW YORK, NY / ACCESS Newswire / February 24, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Voyager Therapeutics, Inc. ("Voyager Therapeutics, Inc.") (NASDAQ:VYGR) concerning possible violations of federal securities laws. Voyager issued a press release on February 11, 2025, "announc[ing] it has decided to assess alternate payloads related to its gene therapy program for superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS)", stating that "[e]merging preclinical data indicate the siRNA payload component of VY9323 does not meet our high standards due to what appears to be an off-target effect resulting in a narrowed therapeutic window. |
accessnewswire.com |
2025-02-24 23:30:00 |
Czytaj oryginał (ang.) |
| VOYAGER ALERT: Bragar Eagel & Squire, P.C. is Investigating Voyager Therapeutics, Inc. on Behalf of Voyager Stockholders and Encourages Investors to Contact the Firm |
NEW YORK, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Voyager Therapeutics, Inc. (“Voyager” or the “Company”) (NASDAQ:VYGR) on behalf of Voyager stockholders. Our investigation concerns whether Voyager has violated the federal securities laws and/or engaged in other unlawful business practices. |
globenewswire.com |
2025-02-24 23:00:00 |
Czytaj oryginał (ang.) |
| VYGR ALERT- Levi & Korsinsky Has Commenced an Investigation on Behalf of Voyager Therapeutics, Inc. Shareholders Who Lost Money |
NEW YORK, NY / ACCESS Newswire / February 24, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Voyager Therapeutics, Inc. ("Voyager Therapeutics, Inc.") (NASDAQ:VYGR) concerning possible violations of federal securities laws. Voyager issued a press release on February 11, 2025, "announc[ing] it has decided to assess alternate payloads related to its gene therapy program for superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS)", stating that "[e]merging preclinical data indicate the siRNA payload component of VY9323 does not meet our high standards due to what appears to be an off-target effect resulting in a narrowed therapeutic window. |
accessnewswire.com |
2025-02-24 12:30:00 |
Czytaj oryginał (ang.) |
| Levi & Korsinsky Reminds Voyager Therapeutics, Inc. Investors of the Ongoing Investigation into Potential Violations of Securities Laws - VYGR |
NEW YORK, NY / ACCESS Newswire / February 23, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Voyager Therapeutics, Inc. ("Voyager Therapeutics, Inc.") (NASDAQ:VYGR) concerning possible violations of federal securities laws. Voyager issued a press release on February 11, 2025, "announc[ing] it has decided to assess alternate payloads related to its gene therapy program for superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS)", stating that "[e]merging preclinical data indicate the siRNA payload component of VY9323 does not meet our high standards due to what appears to be an off-target effect resulting in a narrowed therapeutic window. |
accessnewswire.com |
2025-02-23 12:19:00 |
Czytaj oryginał (ang.) |
| An Investigation Has Been Launched Into Voyager Therapeutics, Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm |
LOS ANGELES, CA / ACCESS Newswire / February 23, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Voyager Therapeutics, Inc. ("Voyager" or "the Company") (NASDAQ:VYGR) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. |
accessnewswire.com |
2025-02-23 12:00:00 |
Czytaj oryginał (ang.) |
| Voyager Therapeutics, Inc. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by Voyager Therapeutics, Inc. (VYGR) |
NEW YORK, NY / ACCESS Newswire / February 22, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Voyager Therapeutics, Inc. ("Voyager Therapeutics, Inc.") (NASDAQ:VYGR) concerning possible violations of federal securities laws. Voyager issued a press release on February 11, 2025, "announc[ing] it has decided to assess alternate payloads related to its gene therapy program for superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS)", stating that "[e]merging preclinical data indicate the siRNA payload component of VY9323 does not meet our high standards due to what appears to be an off-target effect resulting in a narrowed therapeutic window. |
accessnewswire.com |
2025-02-22 20:01:00 |
Czytaj oryginał (ang.) |
| The Schall Law Firm Invites Shareholders With Losses In Voyager Therapeutics, Inc. To Join A Securities Fraud Investigation |
LOS ANGELES, CA / ACCESS Newswire / February 22, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Voyager Therapeutics, Inc. ("Voyager" or "the Company") (NASDAQ:VYGR) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. |
accessnewswire.com |
2025-02-22 13:00:00 |
Czytaj oryginał (ang.) |
| VYGR Investors Have Opportunity to Join Voyager Therapeutics, Inc. Fraud Investigation with the Schall Law Firm |
LOS ANGELES , Feb. 21, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Voyager Therapeutics, Inc. ("Voyager" or "the Company") (NASDAQ: VYGR) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. |
prnewswire.com |
2025-02-22 00:51:00 |
Czytaj oryginał (ang.) |
| Levi & Korsinsky Reminds Voyager Therapeutics, Inc. Investors of the Ongoing Investigation into Potential Violations of Securities Laws - VYGR |
NEW YORK, NY / ACCESS Newswire / February 21, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Voyager Therapeutics, Inc. ("Voyager Therapeutics, Inc.") (NASDAQ:VYGR) concerning possible violations of federal securities laws. Voyager issued a press release on February 11, 2025, "announc[ing] it has decided to assess alternate payloads related to its gene therapy program for superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS)", stating that "[e]merging preclinical data indicate the siRNA payload component of VY9323 does not meet our high standards due to what appears to be an off-target effect resulting in a narrowed therapeutic window. |
accessnewswire.com |
2025-02-21 13:30:00 |
Czytaj oryginał (ang.) |
| An Investigation Has Been Launched Into Voyager Therapeutics, Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm |
LOS ANGELES, CA / ACCESS Newswire / February 21, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Voyager Therapeutics, Inc. ("Voyager" or "the Company") (NASDAQ:VYGR) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. |
accessnewswire.com |
2025-02-21 13:00:00 |
Czytaj oryginał (ang.) |
| Voyager Therapeutics, Inc. Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details - VYGR |
NEW YORK, NY / ACCESS Newswire / February 21, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Voyager Therapeutics, Inc. ("Voyager Therapeutics, Inc.") (NASDAQ:VYGR) concerning possible violations of federal securities laws. Voyager issued a press release on February 11, 2025, "announc[ing] it has decided to assess alternate payloads related to its gene therapy program for superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS)", stating that "[e]merging preclinical data indicate the siRNA payload component of VY9323 does not meet our high standards due to what appears to be an off-target effect resulting in a narrowed therapeutic window. |
accessnewswire.com |
2025-02-21 12:45:00 |
Czytaj oryginał (ang.) |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Voyager Therapeutics, Inc. - VYGR |
NEW YORK CITY, NY / ACCESS Newswire / February 21, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Voyager Therapeutics, Inc ("Voyager" or the "Company") (NASDAQ:VYGR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accessnewswire.com |
2025-02-21 12:00:00 |
Czytaj oryginał (ang.) |
| Lost Money on Voyager Therapeutics, Inc. (VYGR)? You May Have Been Affected by Fraud - Contact Levi & Korsinsky |
NEW YORK, NY / ACCESS Newswire / February 20, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Voyager Therapeutics, Inc. ("Voyager Therapeutics, Inc.") (NASDAQ:VYGR) concerning possible violations of federal securities laws. Voyager issued a press release on February 11, 2025, "announc[ing] it has decided to assess alternate payloads related to its gene therapy program for superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS)", stating that "[e]merging preclinical data indicate the siRNA payload component of VY9323 does not meet our high standards due to what appears to be an off-target effect resulting in a narrowed therapeutic window. |
accessnewswire.com |
2025-02-20 23:15:00 |
Czytaj oryginał (ang.) |
| 3 Biotech Stocks With Promising Gene Therapies to Watch Out in 2025 |
We have picked three biotech stocks with promising gene therapies in their portfolios/pipelines that are likely to perform well in 2025. |
zacks.com |
2024-12-17 12:01:04 |
Czytaj oryginał (ang.) |
| Wall Street Analysts See a 152.53% Upside in Voyager Therapeutics (VYGR): Can the Stock Really Move This High? |
The average of price targets set by Wall Street analysts indicates a potential upside of 152.5% in Voyager Therapeutics (VYGR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. |
zacks.com |
2024-12-03 12:55:36 |
Czytaj oryginał (ang.) |
| Wedbush upgrades Voyager to Outperform on pipeline progress |
Wedbush upgraded Voyager Therapeutics to Outperform from Neutral with a price target of $11, up from $7, after assuming coverage of the name. The firm added the company's tau antibody for Alzheimer's disease program and the AAV-mediated siRNA program for amyotrophic lateral sclerosis caused by mutations in the SOD1 gene into its valuation. Voyager's clinical and preclinical data that became available recently should allow for improved visibility into potential clinical outcomes for both programs, the analyst tells investors in a research note. With the pipeline moving forward closer to clinical entries and data readouts, and the shares trading near 52-week low, Wedbush believes Voyager represents an attractive investment opportunity "for investors with patience that are willing to tolerate the high risks associated with early stage clinical programs for neurodegenerative disorders." |
https://thefly.com |
2024-11-29 08:50:54 |
Czytaj oryginał (ang.) |
| Voyager Therapeutics, Inc. (VYGR) Q3 2024 Earnings Call Transcript |
Voyager Therapeutics, Inc. (NASDAQ:VYGR ) Q3 2024 Results Earnings Conference Call November 12, 2024 4:30 PM ET Company Participants Trista Morrison - Chief Corporate Affairs Officer and Chief of Staff to the CEO Alfred Sandrock - President and Chief Executive Officer Toby Ferguson - Chief Medical Officer Todd Carter - Chief Scientific Officer Nathan Jorgensen - Chief Financial Officer Conference Call Participants Phil Nadeau - TD Cowen Jack Allen - Robert W. Baird Joon Lee - Truist Securities Jay Olson - Oppenheimer & Co. Lili Nsongo - Leerink Partners Patrick Trucchio - HC Wainwright Operator Good afternoon, and welcome to the Voyager Therapeutics Third Quarter 2024 Financial Results Conference Call. |
seekingalpha.com |
2024-11-13 01:07:47 |
Czytaj oryginał (ang.) |
| Voyager Therapeutics (VYGR) Reports Q3 Loss, Tops Revenue Estimates |
Voyager Therapeutics (VYGR) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.45. This compares to loss of $0.59 per share a year ago. |
zacks.com |
2024-11-12 20:21:16 |
Czytaj oryginał (ang.) |
| Voyager Reports Third Quarter 2024 Financial and Operating Results |
- Enrollment and dosing complete in single ascending dose clinical trial of anti-tau antibody VY7523 for Alzheimer's; on track to generate top-line data H1 2025 - |
globenewswire.com |
2024-11-12 18:01:00 |
Czytaj oryginał (ang.) |
| Voyager Therapeutics to Present at Multiple Upcoming Investor Conferences |
LEXINGTON, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the Company will participate in multiple upcoming investor conferences: |
globenewswire.com |
2024-11-06 09:00:00 |
Czytaj oryginał (ang.) |
| Voyager Therapeutics Announces Third Quarter 2024 Conference Call and Webcast |
LEXINGTON, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced it will report third quarter 2024 financial and operating results after market close on Tuesday, November 12, 2024. Subsequently, the Company will host a conference call and webcast at 4:30 p.m. ET. |
globenewswire.com |
2024-11-05 09:00:00 |
Czytaj oryginał (ang.) |
| Voyager Therapeutics (VYGR) Expected to Beat Earnings Estimates: Can the Stock Move Higher? |
Voyager Therapeutics (VYGR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2024-10-28 13:05:20 |
Czytaj oryginał (ang.) |
| Strength Seen in Voyager Therapeutics (VYGR): Can Its 17.5% Jump Turn into More Strength? |
Voyager Therapeutics (VYGR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road. |
zacks.com |
2024-10-07 10:21:08 |
Czytaj oryginał (ang.) |
| Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
LEXINGTON, Mass., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, has entered into an employment agreement with a newly hired employee that, among other things, provides for the grant to such employee of a non-qualified stock option and restricted stock units as an inducement material to such employee's entering into employment with Voyager. The inducement awards were approved by the Compensation Committee of Voyager's Board of Directors in accordance with Nasdaq Stock Market Listing Rule 5635(c)(4). The option award became effective on August 28, 2024, and the restricted stock unit award is scheduled to become effective on October 1, 2024. |
globenewswire.com |
2024-08-29 20:01:00 |
Czytaj oryginał (ang.) |
| Voyager Therapeutics to Present at Multiple Upcoming Investor Conferences |
LEXINGTON, Mass., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the company will participate in multiple upcoming investor conferences: |
globenewswire.com |
2024-08-29 11:00:00 |
Czytaj oryginał (ang.) |
| Voyager: Anti-Tau Antibody Differentiation For AD Treatment Could Boost Prospects |
Voyager Therapeutics, Inc. initial safety and PK data from the phase 1a study using VY7523 for the treatment of patients with Alzheimer's Disease expected 1st half of 2025. Targeting the C-terminal for AD patients instead of N-terminal domain could end up resulting in a significantly greater reduction of tau protein. The global Alzheimer's Disease Therapeutics market is expected to reach $30.8 billion by 2033. |
seekingalpha.com |
2024-08-26 19:24:01 |
Czytaj oryginał (ang.) |
| 7 Biotech Stocks to Buy for Their Game-Changing Potential |
With the market struggling amid rising recession fears, now may be the ideal time to consider biotech stocks. First, the sector itself is a financially lucrative one. |
investorplace.com |
2024-08-08 10:00:00 |
Czytaj oryginał (ang.) |
| Voyager Therapeutics to Present at Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase |
LEXINGTON, Mass., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the company will participate in a fireside chat at the Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase on August 14, 2024, at 9:30 a.m. ET. |
globenewswire.com |
2024-08-07 11:00:00 |
Czytaj oryginał (ang.) |
| Voyager Therapeutics (VYGR) Reports Q2 Loss, Tops Revenue Estimates |
Voyager Therapeutics (VYGR) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.38. This compares to loss of $0.51 per share a year ago. |
zacks.com |
2024-08-06 22:21:37 |
Czytaj oryginał (ang.) |
| Voyager Therapeutics Reports Second Quarter 2024 Financial and Operating Results |
- Top-line safety and pharmacokinetic data expected in H1 2025 from recently initiated single ascending dose trial of anti-tau antibody for Alzheimer's disease - |
globenewswire.com |
2024-08-06 20:01:00 |
Czytaj oryginał (ang.) |
| Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
LEXINGTON, Mass., July 23, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, has entered into an employment agreement with Eric Hall, Ph.D., M.B.A. that, among other things, provides for the grant to Dr. Hall of a non-qualified stock option and restricted stock units as an inducement material to Dr. Hall's entering into employment with Voyager. The inducement awards were approved by the Compensation Committee of Voyager's Board of Directors in accordance with Nasdaq Stock Market Listing Rule 5635(c)(4). The option award became effective on July 22, 2024, and the restricted stock unit award is scheduled to become effective on October 1, 2024. |
globenewswire.com |
2024-07-23 20:01:00 |
Czytaj oryginał (ang.) |
| Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
LEXINGTON, Mass., July 09, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, has entered into an employment agreement with Nathan Jorgensen, Ph.D., M.B.A. that, among other things, provides for the grant to Dr. Jorgensen of a non-qualified stock option and restricted stock units as an inducement material to Dr. Jorgensen's entering into employment with Voyager. The inducement awards were approved by the Compensation Committee of Voyager's Board of Directors in accordance with Nasdaq Stock Market Listing Rule 5635(c)(4). The option award became effective on July 8, 2024, and the restricted stock unit award is scheduled to become effective on October 1, 2024. |
globenewswire.com |
2024-07-09 20:01:00 |
Czytaj oryginał (ang.) |
| Voyager Therapeutics to Present at Multiple Virtual Investor Conferences |
LEXINGTON, Mass., June 13, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the company will participate in fireside chats at the TD Cowen Genetic Medicines & RNA Summit on June 20, 2024, at 1:35 p.m. ET and at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference on June 27, 2024, at 7:00 a.m. ET. |
globenewswire.com |
2024-06-13 20:01:00 |
Czytaj oryginał (ang.) |